Anti-Tumor Necrosis Factor alfa (TNF-alfa) antibodies / Tumor Necrosis Factor alfa (TNF-alfa) inhibitors & Crohn’s Disease (CD)

The benefit of TNF-alfa antibodies / TNF inhibitors early in the course of Crohn’s Disease (CD) is still controversial, with some studies showing better outcomes but others not
Hamdeh et al. 2020 Inflamm Bowel Dis 26: 1808–1818

According a systematic review using anti-TNF-alpha earlier in the treatment of Crohn’s disease (within 3 years) may improve clinical outcomes compared to late administration in terms of achieving early clinical remission, clinical response, disease progression, and the need for surgery.
Hamdeh et al. 2020 Inflamm Bowel Dis 26: 1808–1818

Although immunosuppressive therapies such as antibodies targeting TNF can be effective, initial treatment fails in approximately 40% of patients and initial responders frequently experience relapse
Plichta et al. 2019 Cell 178: 1041-1056

see also:
[I…